newsfilter

$GENZ News

Last published 7mo ago

  • 7mo agoBJKGENZVanEck Converts Gaming ETF into GENZ ETF Targeting Digital Native EconomyBusiness WireAs GenZ and millennials reshape the economy through digital-first behaviors, VanEck is relaunching its Gaming ETF (BJK) as the VanEck Digital Native Economy ETF (GENZ), targeting the structural changes across payments,
  • 15y agoGENZGenzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender SharesBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) announced today that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74.00 and one contingent value right, per share. The Board recommends that all Genzyme shareholders tender their shares into t ...
  • 15y agoGENZGenzyme Completes Sale of Pharmaceuticals Business to International Chemical Investors GroupBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that it has completed the sale of its pharmaceutical intermediates business to International Chemical Investors Group (ICIG).
  • 15y agoGENZGenzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant ProgramBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL Awards). A global grant program, the Genzyme PAL Awards will support non-profit organizations that work on behalf of patients living with lysosomal storage disorders (LSDs), a group of rare, inher ...
  • 15y agoGENZThree-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Further Improvement Across All EndpointsBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint. The results were p ...
  • 15y agoGENZGenzyme Reports Financial Results for Fourth Quarter of 2010 and Full YearBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported fourth-quarter 2010 results that reflect increasing supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta), revenue growth across all major product lines, and reductions in operating expenses. Earlier today Genzyme and sanofi-aventis announced that they have reached a definitive agreement un ...
  • 15y agoGENZGenzyme Reports Financial Results for Fourth Quarter of 2010 and Full YearBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported fourth-quarter 2010 results that reflect increasing supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta), revenue growth across all major product lines, and reductions in operating expenses. Earlier today Genzyme and sanofi-aventis announced that they have reached a definitive agreement un ...
  • 15y agoGENZGenzyme Completes Sale of Diagnostics Business to Sekisui Chemical Co.Business WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.
  • 15y agoGENZGenzyme Will Allow Sanofi-Aventis to Conduct Due DiligenceBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) announced today that ongoing discussions with Sanofi-Aventis have progressed to the point where Genzyme’s board has authorized the company to enter into a confidentiality agreement with Sanofi-Aventis in order to allow Sanofi to conduct due diligence. Discussions between Genzyme’s advisors and Sanofi’s advisors and between Genzyme and ...
  • 15y agoGENZGenzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme®Business WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today announced that it will build an additional manufacturing plant in Geel, Belgium, to support the long-term growth of Myozyme® and Lumizyme® for Pompe disease. The company held a ceremony today in Geel to mark the start of construction of the new €250 million plant, which will include 8,000 liters of production capacity, a complet ...
  • 15y agoGENZGenzyme Financial Recovery Continues in Fourth QuarterBusiness WireCAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that preliminary fourth-quarter revenue grew 23 percent to $1.15 billion from $938 million in the fourth quarter of 2009. For the year, revenue was $4.1 billion compared with $4.0 billion in 2009. Fourth-quarter revenue from the Personalized Genetic Health business grew 46 percent compared with the same period in 2009, ...